Genfit S.A.'s EBIT is $-94M, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
The latest EBIT for GNFT.PA is $-94M as of June 2026. That compares with $21M in the prior-year period — down 553.3% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Genfit S.A.'s historical trend and sector peers before judging valuation or financial health.
Over the past year, GNFT.PA's EBIT moved from $21M to $-94M — a 553.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Genfit S.A.'s operating scale or balance-sheet position.
Against Healthcare companies, GNFT.PA currently prints $-94M for EBIT, while the sector average sits near $110B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Genfit S.A.'s growth, margins, and balance sheet.
A EBIT figure of $-94M for GNFT.PA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.
After noting GNFT.PA's EBIT ($-94M), review year-over-year change from $21M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.